[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100167343":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":32,"centralContacts":27,"locations":35,"responsibleParty":47,"collaborators":27,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":27,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":27,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":27,"overallStatus":68,"whyStopped":27,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":27,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Boehringer Ingelheim","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment A","EXPERIMENTAL","high dose of empagliflozin after overnight fasting for at least 10 h",[13],"Drug: Empagliflozin",{"label":15,"type":10,"description":16,"interventionNames":17},"Treatment B","high dose of empagliflozin after a standardised high fat breakfast",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Treatment C","low dose empagliflozin after overnight fasting for at least 10 h",[13],[23,28,30],{"type":24,"name":25,"description":11,"armGroupLabels":26,"otherNames":27},"DRUG","Empagliflozin",[9],null,{"type":24,"name":25,"description":20,"armGroupLabels":29,"otherNames":27},[19],{"type":24,"name":25,"description":16,"armGroupLabels":31,"otherNames":27},[15],[33],{"name":5,"affiliation":5,"role":34},"STUDY_CHAIR",[36],{"facility":37,"status":27,"city":38,"state":27,"zip":27,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":27},"1245.79.1 Boehringer Ingelheim Investigational Site","Biberach","Germany","DE",{"type":42,"coordinates":43},"Point",[44,45],8.03333,48.33333,{"lat":45,"lon":44},{"type":48,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100167343","phase-1-investigation-of-the-effect-of-food-on-the-bioavailability-of-a-25-mg-empagliflozin-tablet-as-well-as-assessment-of-dose-proportionality-between-10-mg-and-25-mg-empagliflozin-tablets-under-fasting-conditions-100167343",true,"NCT01451775","Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.","Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet and Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets in an Open, Randomised, Single Dose, Three-period Cross-over Study in Healthy Male and Female Subjects","Inclusion criteria:\n\n1\\. Healthy male and female subjects\n\nExclusion criteria:\n\n1\\. Any relevant deviation from healthy conditions","ALL","18 Years","55 Years",{"count":60,"type":61},18,"ACTUAL","INTERVENTIONAL",[64],"PHASE1","Investigation of food effect on the bioavailability of a 25 mg empagliflozin tablet and assessment of dose proportionality between 10 mg and 25 mg empagliflozin tablets under fasting conditions.",[67],"Healthy","COMPLETED","2014-06-26",{"date":71,"type":72},"2014-06-27","ESTIMATED",{"date":74,"type":27},"2011-10",{"name":5,"class":6},1]